Blog Coverage: Valeant Announces the Pricing for SILIQ as the Lowest Priced Injectable Biologic for Moderate-To-Severe Plaque Psoriasis

Upcoming AWS Coverage on Adamis Pharmaceuticals Post-Earnings Results

LONDON, UK / ACCESSWIRE / April 24, 2017 / Active Wall St. blog coverage looks at the headline from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) as the Company announced on April 21, 2017, that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the Company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Valeant Pharmaceuticals International’s competitors within the Drug Delivery space, Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), is estimated to report earnings on May 12, 2017. AWS will be initiating a research report on Adamis Pharma following the release of its next earnings results.

Today, AWS is promoting its blog coverage on VRX; touching on ADMP. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

What is SiliQ?

SILIQ is a novel human monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SiliQ for which Valeant got the rights from AstraZeneca binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor. By blocking IL-17 from activating the receptor, SILIQ prevents the body from receiving signals that may lead to inflammation. SILIQ is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. In February 2017, the US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SILIQ, the sales and marketing of SILIQ are expected to commence in the US during H2 2017.

Valeant stated that the SILIQ’s price rate is the lowest injectable biologic psoriasis treatment currently on the market. SILIQ will also be included in the Company’s patient access program to further offer financial support and access to patients.

“The Patient Access and Pricing Committee was constructed to help our company ensure patients have the best possible access to our products. Our goal with SILIQ is to provide outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis,” said Joseph Papa, Chairman and CEO of Valeant.

In May 2016, Valeant established the PAPC to be responsible for the pricing of the Company’s drugs. The PAPC ensures that the Canadian firm’s pricing, contracting, compliance, and reimbursement strategies are consistent and compliant with all relevant laws, regulations and guidance, as well as the Company’s position on patient-affordable access to medicines. The Company’s Board of Directors oversees the committee, which is chaired by Papa and includes a multi-disciplinary team of Valeant employees, including doctors, scientists, and other executives.

SILIQ carries a Black Box Warning for risk in patients with a history of suicidal thoughts or behavior. SILIQ was approved with a Risk Evaluation and Mitigation Strategy (REMS) involving a one-time enrollment for physicians and one-time informed consent for patients.

Stock Performance

At the close of trading session on Friday, April 21, 2017, Valeant Pharma’s stock price declined 4.17% to end the day at $8.51. A total volume of 27.98 million shares were exchanged during the session, which was above the 3-month average volume of 18.47 million shares. The stock currently has a market cap of $2.95 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 460379